Dear Sir/Madam,
Ref:
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
This is in reference to our intimation dated August 14, 2026, wherein we had informed regarding the Good Manufacturing Practices (GMP) inspection conducted by the United States Food & Drug Administration (USFDA) at our formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad. We wish to inform you that the USFDA has classified the inspection outcome as ‘Voluntary Action Indicated (VAI)’ and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3).
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR